Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00962689 · ClinicalTrials.gov registry record

Clinical Study to Improve Diagnosis and Treatment of Sinusitis

A clinical trial, sponsored by Ohio State University.

Completed
Registry status
38
Enrollment target

NCT00962689 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 38 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00962689 has completed, sponsored by Ohio State University.

COMPLETED
Registry status
38 participants
Enrollment target

Study Summary

Chronic rhinosinusitis (CRS) is the most common chronic medical condition that affects Americans between 18-44 years of age. While significant advances have been made in the understanding of the molecular pathogenesis underlying many subtypes of CRS, this has not translated into widespread changes in how physicians manage adult or pediatric CRS. The focus of this study is intended to develop testing methods to improve the objectivity and specificity of diagnosis and allow for individualized therapy with less invasive, customized treatments instead of the traditional, empiric based, and radically exenterative therapies commonly employed in clinical practice. Specifically, it is now known that many patients with CRS have a greater concentration of non-typeable Haemophilus influenzae (NTHI) in the bacterial biofilms located within their sinus cavities compared to healthy patients. The specific hypothesis behind the proposed research is that the presence of NTHI biofilms, which are known to be highly recalcitrant, are positively correlated with the development of CRS and that unique lipooligosaccharides and inflammatory byproducts obtained from nasopharyngeal lavage fluids and/or swabs of sinus secretions may be used as a non-invasive biomarker for CRS. As a result, patients with symptoms of CRS specifically associated with NTHI biofilms could possibly obtain a non-invasive test in the physician's office that would allow the clinician to make a more accurate diagnosis and objectively follow each patient's responsiveness to customized therapy.

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2009-08
Est. Completion 2013-11

Sponsor

Ohio State University

552 total trials

What the Registry Record Tells You About NCT00962689

The ClinicalTrials.gov registry entry for NCT00962689 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00962689 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00962689 about?

NCT00962689 is a clinical study titled "Clinical Study to Improve Diagnosis and Treatment of Sinusitis". Chronic rhinosinusitis (CRS) is the most common chronic medical condition that affects Americans between 18-44 years of age. While significant advances have been made in the understanding of the molecular pathogenesis underlying many subtypes of CRS, this has not translated into widespread changes i...

What is the current status of trial NCT00962689?

This trial is currently completed. The enrollment target is 38 participants. The study started on 2009-08. Estimated completion is 2013-11.

Who is sponsoring clinical trial NCT00962689?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.